Protocol
11-015
Full Title
A Phase I/II Trial of HSP90 Inhibitor AUY-922 in Patients with Lung Adenocarcinoma with "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors
Purpose
The purpose of this study is to find the highest dose of an investigational drug called AUY-922 that can be given safely with the drug erlotinib in patients with lung adenocarcinoma that initially responded to erlotinib or gefitinib and then began growing again. AUY-922 inhibits Heat Shock Protein 90, which cancer cells use to grow. Researchers want to see if adding AUY-922 to erlotinib is more effective than erlotinib or gefitinib alone.
Erlotinib is taken orally (by mouth), while AUY-922 is given intravenously (by vein).
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have lung adenocarcinoma (stage IIIB or IV) that initially responded to erlotinib or gefitinib OR has a documented mutation in the EGFR gene.
- Patients must have had erlotinib or gefitinib in the month prior to entering the study, and must have taken one of these drugs for at least 6 months.
- At least 4 weeks must have passed since prior conventional chemotherapy, radiation therapy, or major surgery (2 weeks since palliative radiation) and entry into the study.
- Patients with a history of inflammatory bowel disease may not participate.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Gregory Riely at 646-888-4199.
Disease(s)
Lung Cancer
Lung Cancer, Non-Small Cell: Lung Adenocarcinoma
Related Diseases
